This is a guest post by J. Carter Thompson, of Baker Donelson, and it’s for a good cause:

*************

DRI’s Drug and Medical Device Committee will hold its 26th annual Seminar on May 20-21, 2010, at the San Francisco Marriott, in San Francisco, California.  The Seminar is the preeminent program for practitioners who represent pharmaceutical and medical device manufacturers. The Seminar will feature a number of nationally recognized attorneys [editor’s note:  including Bob Limbacher of Dechert], both in-house and outside counsel, and other professionals, who will address cutting-edge topics that are relevant to all who practice in this area, whether they are associates, lead trial counsel, or in-house counsel. This year’s program will offer a mixture of presentations, such as trial skills demonstrations, panel discussions and individual presentations from leaders in their practice areas. In addition to the outstanding program, there will be numerous networking opportunities, including the annual Young Lawyers Blockbuster.

Seminar speakers will address key topics such as the latest developments in preemption following Levine and Riegel, defending drug and device cases on the science, presenting clinical trial evidence to a jury, new developments in innovator liability, and defending consumer protection claims. Those who attend may earn up to 12.5 hours of CLE, including 1.0 hours of ethics.